ATAI | tickerfilter.com

Fundamental analysis

30%

Profitability 25%

Dept financing 5%

Liquidity 75%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

3.36%

1 Month

-26.79%

3 Months

4.24%

6 Months

-8.89%

1 Year

-12.14%

2 Year

-48.54%

Key data

Stock price

$1.23

P/E Ratio

-3.76

DAY RANGE

N/A - N/A

EPS

-$0.36

52 WEEK RANGE

$1.10 - $2.85

52 WEEK CHANGE

-$20.65

MARKET CAP

218.139 M

YIELD

N/A

SHARES OUTSTANDING

167.799 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

11/14/2024

BETA

1.43

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,333,364

AVERAGE 30 VOLUME

$1,221,243

Company detail

CEO: Florian Brand
Region: US
Website: atai.life
Employees: 80
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Atai Life Sciences N.V. operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD)

ATAI - ATAI Life Sciences N.V.